How RWE can support drug development during COVID-19 and beyond: Q&A with Dr. Diana Brainard of Gile...

The COVID-19 pandemic introduced novel challenges for global biopharma organizations, as many adapted their clinical trial operations while working to develop lifesaving interventions. At Gilead Sciences, this need to quickly pivot led to an increase...

Indirect measures: False negatives

4 part series [Part 3] of Matching Accuracy Metrics | Catch up on Part 1 and Part 2 By: Austin Eliazar, Chief Data Scientist, HealthVerity False negatives — the missed links between records — are the most obvious errors in a matching system. They can...

Indirect measures: False negatives

4 part series [Part 3] of Matching Accuracy Metrics | Catch up on Part 1 and Part 2 By: Austin Eliazar, Chief Data Scien...

Indirect Measures: False Positives

4 part series [Part 2] of Matching Accuracy Metrics By: Austin Eliazar, Chief Data Scientist, HealthVerity

Matching Accuracy Metrics: How to objectively evaluate the performance of a de-identification soluti...

4 part series [Part 1] of Matching Accuracy Metrics By: Austin Eliazar, Chief Data Scientist, HealthVerity

Basics of digital trust: What are you really opting into?

Are you getting the full picture with healthcare data?

Why social determinants of health are necessary for the complete patient journey. Most pharmaceutical and payer research...

CCPA is Coming

What you need to know and how to prepare By: John Chaisson, Data Privacy & Blockchain, HealthVerity

The privacy conversation is now public: Expectations for 2019

Subscribe to the HealthVerity blog